These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 26898325)

  • 1. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
    Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
    Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
    Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
    J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
    Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
    Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
    Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
    Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
    Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
    Vrontis K; Economidou SC; Fotopoulos G
    Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.
    Lowczak A; Kolasinska-Cwikla A; Osowiecka K; Glinka L; Palucki J; Rzepko R; Doboszynska A; Cwikla JB
    Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33525370
    [No Abstract]   [Full Text] [Related]  

  • 13. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung.
    Kujtan L; Muthukumar V; Kennedy KF; Davis JR; Masood A; Subramanian J
    J Thorac Oncol; 2018 May; 13(5):707-714. PubMed ID: 29391287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
    Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
    Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China.
    Wang Z; Wu Y; Lu T; Xu Y; Chen M; Zhong W; Zhao J; Wang M
    Cancer Med; 2024 Jan; 13(1):e6834. PubMed ID: 38180312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
    Kozuki T; Fujimoto N; Ueoka H; Kiura K; Fujiwara K; Shiomi K; Mizobuchi K; Tabata M; Hamazaki S; Tanimoto M
    J Cancer Res Clin Oncol; 2005 Mar; 131(3):147-51. PubMed ID: 15538626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
    Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
    Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
    Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.